NuVasive touts results of PEEK implant study

NuVasive Cohere porous PEEK cervical implant (Image from NuVasive)

NuVasive (NSDQ:NUVA) today announced the results of a study that showed its Cohere porous polyetheretherketone (PEEK) implant improved early outcomes over structural allograft and smooth PEEK in anterior cervical discectomy and fusion (ACDF) procedures.

In the study of 167 patients with degenerative cervical disc disease, those who underwent ACDF using Cohere porous PEEK exhibited significant clinical improvements such as better neck disability scores relative to preoperative scores, better outcomes than other treatments as early as six weeks, and sustained improvements relative to other treatments through 12-months post-op, the company reported. The study also showed that patients treated with smooth PEEK exhibited significant improvements at three months post-procedure. Structural allograft patients began to improve over baseline by six weeks.

The study, “Early Clinical Outcomes Comparing Porous PEEK, Smooth PEEK, and Structural Allograft Interbody Devices for Anterior Cervical Discectomy and Fusion,” was published online in the Journal of Spine & Neurosurgery.

“This is the first comparative study between NuVasive’s Cohere porous PEEK, smooth PEEK and allograft interbody spacers in ACDF, and it was found that patients treated with a Porous PEEK implant experienced incrementally improved early clinical improvements, which were sustained through the course of the study,” said NuVasive senior director of medical affairs Kyle Malone in a prepared statement. “Studies like this both corroborate the preclinical data as well as reaffirm NuVasive’s commitment to clinical research and the necessity of having this as part of the product development process so we continually offer surgeons the best, most clinically proven technologies for their patients.”

Cohere porous PEEK has 3D porous architecture designed to elicit and encourage bone in-growth and stabilization without compromising implant strength or radiolucency, according to NuVasive. The San Diego-based company acquired Cohere and other interbody implants when it bought Vertera Spine in 2017.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW